Caplin Point Laboratories Ltd
Caplin Point Laboratories Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Caplin Point expects 20-25% growth in sales/revenue in the next 2 years (FY28 timeframe). - Growth beyond 2 years is anticipated but with a focus on larger geographies and unique products, especially biologicals. - After 2 years, operating margins could improve to around 40%, if markets remain favorable. - The company is expanding injectable manufacturing capacity, aiming to be among the top 4-5 injectable exporters from India to the U.S. Caplin Point expects 20-25% growth in sales within the next 24 months (Q2 FY28), driven by market expansion and product distribution improvements.
From Caplin Point Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Caplin Point expects 20-25% growth in sales/revenue in the next 2 years (FY28 timeframe).
- Growth beyond 2 years is anticipated but with a focus on larger geographies and unique products, especially biologicals.
- After 2 years, operating margins could improve to around 40%, if markets remain favorable.
- The company is expanding injectable manufacturing capacity, aiming to be among the top 4-5 injectable exporters from India to the U.S. with 12 lines.
- Expansion plans include new facilities in Mexico and Guatemala for higher revenue and profit.
- Company focuses on bottom-of-the-pyramid essential medicines, targeting growing demand in private markets.
2 more points from Caplin Point Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Caplin Point Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Caplin Point is investing in a new API oncology facility and injectable projects (Caplin One Lab), nearing completion and expected to be operational by December.
- Expansion includes a Vizag facility with received consent to operate, currently scaling up API production.
- Plans to start a factory in Mexico to benefit from government incentives.
- Proposal for a liquid oral facility in Guatemala to boost revenue through liquid product sales in Central America.
- Caplin Steriles US (CSU) has launched 24 products, plans 15 more next year, targeting profitability and portfolio expansion.
2 more points from Caplin Point Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Caplin Point Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders in a quantified manner.
- C.C. Paarthipan and other management highlight ongoing projects like the Caplin One Lab injectable project nearing completion (~INR 90 crores work in progress expected by December).
- There is mention of acquisitions and expansion into new markets (e.g., setting up a factory in Mexico, liquid oral facility in Guatemala), suggesting an expanding pipeline.
- Discussions emphasize increasing sales, cash flow, and profit growth with a confident outlook on future business.
2 more points from Caplin Point Laboratories Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Caplin Point Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹600 Cr, net profit ₹173 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Caplin Point Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wanbury Ltd (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q2 FY26)
42.35 crore, up 21.98% year-on-year from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q2 FY26 investor presentation — and how it ran
- Senores Pharmaceuticals Ltd (Q2 FY26)
Earnings (PAT) growth has been very strong recently (e.g., 131% Y-o-Y growth in Q2) with sustained profitability momentum. Key concall takeaways from Senores…
- Indoco Remedies Ltd (Q2 FY26)
R&D spend will reduce from ~5% to ~4% of sales, focusing on vertically integrated, higher efficiency products. Key concall takeaways from Indoco Remedies Ltd's…
Arthneeti Pro · Annual
Caplin Point Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Caplin Point Laboratories Ltd Q2 FY26 results?
Caplin Point expects 20-25% growth in sales/revenue in the next 2 years (FY28 timeframe). - Growth beyond 2 years is anticipated but with a focus on larger geographies and unique products, especially biologicals. - After 2 years, operating margins could improve to around 40%, if markets remain favorable. - The company is expanding injectable manufacturing capacity, aiming to be among the top 4-5 injectable exporters from India to the U.S. Caplin Point expects 20-25% growth in sales within the next 24 months (Q2 FY28), driven by market expansion and product distribution improvements.
What is Caplin Point Laboratories Ltd share price analysis?
Caplin Point Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 26.3 with a market cap of ₹17,491 Cr. Investors should review the full earnings analysis for detailed insights.
Is Caplin Point Laboratories Ltd planning capital expenditure?
Caplin Point is investing in a new API oncology facility and injectable projects (Caplin One Lab), nearing completion and expected to be operational by December.
Keep Caplin Point Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.